The goal of the CWRU/UHC CFAR Development Core (Core B) is to stimulate AIDS-related research at CWRU and its affiliates by providing resources to enhance research opportunities. This goal will be achieved through targeting the following objectives: 1. Enhancing faculty development through the provision of competitive developmental awards 2. Supporting recruitment of new faculty interested in AIDS research 3. Promoting interactions among investigators at CWRU especially across different scientific disciplines and in areas of AIDS research that are currently under-represented at CWRU. During the next period of award, the Developmental Core will support the following programs: 1. Provision of seed funding as developmental awards to develop preliminary data sufficient to attract independent research grants. Seed funding will support as many as 5 research awards of up to $30,000 targeted to support the research initiatives of young investigators each year. This will be supported by CFAR funds. 2. Provision of a mentoring program to support junior faculty and fellows' development as independent investigators. A comprehensive mentoring program will assure that junior investigators benefit from structured mechanisms to enhance the rigor and quality of their research presentations, manuscripts and research grants. 3. Enhancement of faculty recruitment. Substantial funds obtained from institutional sources will be used to help in the recruitment of new faculty interested in AIDS research. Newly recruited faculty will be allowed to apply for an enhanced developmental award of $90,000 over three years paid using institutional funds administered through the CFAR Developmental Core. 4. Enhancement of core facilities. Institutional funds will be used to provide support of key equipment needed to extend and improve the services of CFAR cores. These awards will be recommended by the Steering Committee (see Core A) following a requests from the Core directors that will be evaluated during CFAR strategic planning meetings. 5. Initiation of new AIDS research. Institutional funds will provide developmental grants to support initiation of new research avenues, especially in areas that are currently under represented in the CFAR. A limited number of developmental grants of up to $50,000 will be awarded on a competitive basis using a parallel procedure to that used to evaluate developmental grants but paid for using institutional funds. For each award, objective criteria will be used to monitor progress and evaluate success. For developmental awards and for the mentoring program, annual determination of programmatic successes and failure will be used to modify the program and award criteria to enhance the chances of success.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-12
Application #
7063048
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
12
Fiscal Year
2005
Total Cost
$232,650
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications